| Sygnia Itrix Health Innovation AMETF
Type: Active ETF |
JSE code: SYGH |
| Benchmark: Solactive Developed Markets Healthcare 150 | Classification: Global Equity |
| Tax-free investing: Allowed (What is tax-free?) | Market cap: R 204 million |
| TIC (TER where TIC not indicated): 0.55000000000000004% (What is TER?) | Distribution: Semi-annual distribution / 14 Jul 2025 – 16.87887 cents per unit | 14 Jan 2026 – 10.30382 cents per unit |
| Top holdings:
Eli Lilly Ord Shs (9.7%), Johnson & Johnson Ord Shs (6.5%), AbbVie Ord Shs (4.5%), Roche Holding Par Shs (3.6%), Novartis Ord Shs (3.5%), Astrazeneca Ord Shs (3.4%), Merck & Co Ord Shs (3.3%), UnitedHealth Group Ord Shs (2.9%), Amgen Ord Shs (2.3%), Abbott Laboratories Ord Shs (2.2%) |
|
| MDD updated: 09 Mar 2026 (Understanding your MDD) | |
| Description:
The fund aims to provide investors access to healthcare innovation stocks and deliver long-term capital growth |
|
All data from the issuer Minimum Disclosure Documents (MDD) and updated as they update their MDDs. Please check all data, we take no responsibility for errors.